News
-
BioDelivery Sciences Announces Completion Of BEMA Buprenorphine Phase 3 Chronic Pain Study
8/1/2011
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.
-
FDA Agrees With Dynavax On Consistency Of HEPLISAV™ Lots
8/1/2011
Dynavax Technologies Corporation today announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) advised the company that "CBER agrees that clinical consistency of three consecutively manufactured lots of HEPLISAV has been demonstrated."
-
Synowledge Announces The Launch Of Regulatory Affairs Services
7/24/2011
Synowledge, LLC, a market leader in pharmacovigilance and related IT services for pharmaceutical and biotechnology companies, is pleased to announce the launch of its Regulatory Affairs service line.
-
Titan Pharmaceuticals Announces Positive Top Line Results In Confirmatory Phase 3 Trial Of Probuphine
7/15/2011
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced positive results from its Phase 3 placebo- and active drug-controlled confirmatory clinical study of Probuphine™, evaluating the safety and efficacy of its investigational drug in treating patients with opioid dependence.
-
Clinilabs And Ambulatory Monitoring Inc. Form Strategic Alliance - Merging The Most Respected Name In Activity Monitoring Equipment With The World's Leading Core
7/8/2011
Clinilabs, a full-service contract research organization that provides early-phase and specialty clinical drug development services to industry, has entered into a strategic alliance with Ambulatory Monitoring, Inc. (AMI), a medical device and service company.
This website uses cookies to ensure you get the best experience on our website. Learn more